LONDON--(BUSINESS WIRE)--Amphion Innovations plc, the developer of life science and medical technology businesses, announces today that it has invested £1 million in its latest Partner Company, Myconostica Ltd, an award winning University of Manchester spin-out.
Myconostica is a company specialising in a new type of ‘molecular’ diagnostic test for infectious diseases, particularly life-threatening respiratory fungal infections, allowing much faster and more precise diagnosis. These tests will have significant health-care benefits, such as reducing death rates, shortening recovery times and hospital stay, and reducing the high cost of care for these types of patients. The Company has secured a significant international intellectual property position in advances in molecular diagnostics including licences from the University of Manchester, the Public Health Research Institute (PHRI) in Newark, New Jersey, and other leading research centres.
